Skip to main content
Donald Baker, PharmD, MBA

Donald Baker, PharmD, MBA

  • Medication-Use Safety PGY2 Preceptor


  • PharmD – University of Tennessee College of Pharmacy, Memphis, Tennesee
  • MBA – University of Memphis, Memphis, Tennessee

Focused Area of Practice

  • Medication Safety
  • Clinical Decision Support
  • Informatics

St. Jude Service

  • Medication Use Safety Team
  • Antibiotic Utilization and Improvement Committee
  • Quality and Patient Safety Committees
  • IS Clinical Council

Research Interests

  • Pharmacogenetics
  • Clinical Decision Support

Selected Publications

Morris SA, Crews KR, Hayden RT, Takemoto CM, Yang W, Baker DK, Broeckel U, Relling MV, Haidar CE. Incorporating GPD genotype to identify patients with G6PD deficiency.   Pharmacogenet Genomics Apr 1;32(3):87-93, 2022.  PMID: 34693927 

Daniels CC, Burlison JD, Baker DK, Robertson J, Sablauer A, Flynn PM, Campbell PK, Hoffman JM.  Pediatrics.  Optimizing Drug-Drug Interaction Alerts Using a Multi-Dimensional Approach. 2019 Mar;143(3):e20174111. Doi: 10.1542/peds.2017-4111. Epub 2019 Feb 13. PMID: 3076-508

Burlison JD, McDaniel RB, Baker DK, Hasan M, Robertson JJ, Howard SC, Hoffman JM. Appl Clin Inform. Using EHR Data to Detect Prescribing Errors in Rapidly Discontinued Orders. 2018 Jan;9(1):82-88. Doi: 10.1055/s-0037-1621703. Epub 2018 Jan 31. PMID: 29388181

Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, Estepp JH, Pei D, Broeckel U, Wang W, Weiss MJ, Relling MV, Hankins J. Pediatrics. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. 2016 Jul;138(1). pii: e20153479. doi: 10.1542/peds.2015-3479.

McDaniel RB, Burlison JD, Baker DK, Hasan M, Robertson J, Hartford C, Howard SC, Sablauer A, Hoffman JM. Alert dwell time: introduction of a measure to evaluate interruptive clinical decision support alerts. J Am Med Inform Assoc 2016 Apr;23(e1):e138-41. doi: 10.1093/jamia/ocv144. Epub 2015 Oct 24.

Call RJ, Burlison JD, Robertson JJ, Scott JR, Baker DK, Rossi MG, Howard SC, Hoffman JM. Adverse drug event detection in pediatric oncology and hematology patients: using medication triggers to identify patient harm in a specialized pediatric patient population.  J Pediatr Sep;165(3):447-52.e4, 2014. Epub 2014 Apr 25.

Hoffman JM, Haidar CE, Wilkinson MR, Crews KR, Baker DK, Kornegay NM, Yang W, Pui CH, Reiss UM, Gaur AH, Howard SC, Evans WE, Broeckel U, Relling MV. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet Mar;166C(1):45-55, 2014. Epub 2014 Mar 11.

Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, Kornegay NM, Yang W, Cross SJ, Howard SC, Freimuth RR, Evans WE, Broeckel U, Relling MV, Hoffman JM. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc Feb;21(e1):e93-9, 2014. Epub 2013 Aug 26.

Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, Stoddard A, Yang W, Smith C, Fernandez CA, Cross SJ, Haidar C, Baker DK, Howard SC, Evans WE, Broeckel U, Relling MV. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther Nov;92(5):563-6, 2012. Epub 2012 Sep 19.

Hoffman JM, Baker DK, Howard SC, Laver JH, Shenep JL. Safe and successful implementation of CPOE for chemotherapy at a children's cancer center. J Natl Compr Canc Netw Feb;9 Suppl 3:S36-50, 2011.

Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm Jan 15;68(2):143-50, 2011. doi: 10.2146/ajhp100113.

Shenep JL, Flynn PM, Baker DK, Hetherington SV, Hudson MM, Hughes WT, Patrick CC, Roberson PK, Sandlund JT, Santana VM, Sixbey JW, Slobod KS. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis Jan;32(1):36-43, 2001. Epub 2000 Dec 8.

Stevens RC, Reed MD, Shenep JL, Baker DK, Foulds G, Luke DR, Blumer JL, Rodman JH. Pharmacokinetics of azithromycin after single- and multiple-doses in children.  Pharmacotherapy Sep-Oct;17(5):874-80, 1997.

Kaste SC, Young CW, Holmes TP, Baker DK. Effect of helical CT on the frequency of sedation in pediatric patients. AJR Am J Roentgenol Apr;168(4):1001-3, 1997.

Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol Feb;10(2):311-5, 1992.

Goren MP, Baker DK Jr, Shenep JL. Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr Infect Dis J May;8(5):278-82, 1989.

Mirro J Jr, Crom WR, Kalwinsky DK, Santana VM, Baker DK, Belt J. Targeted plasma drug concentration: a new therapeutic approach to relapsed nonlymphoblastic leukemia in children. Haematol Blood Transfus 32:82-7, 1989.

Shenep JL, Hughes WT, Roberson PK, Blankenship KR, Baker DK Jr, Meyer WH, Gigliotti F, Sixbey JW, Santana VM, Feldman S, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med Oct 20;319(16):1053-8, 1988.

Goren MP, Viar MJ, Shenep JL, Wright RK, Baker DK, Kalwinsky DK. Monitoring serum aminoglycoside concentrations in children with amphotericin B nephrotoxicity. Pediatr Infect Dis J Oct;7(10):698-703, 1988.

Last update: October 2022